Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
1st-line treatment (1) 1
adult (1) 1
aged (1) 1
analysis (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
bevacizumab - administration & dosage (1) 1
camptothecin - administration & dosage (1) 1
camptothecin - analogs & derivatives (1) 1
cancer therapies (1) 1
cetuximab - administration & dosage (1) 1
chemotherapy (1) 1
colorectal cancer (1) 1
colorectal neoplasms - drug therapy (1) 1
colorectal neoplasms - mortality (1) 1
colorectal neoplasms - pathology (1) 1
depth (1) 1
female (1) 1
fluorouracil - administration & dosage (1) 1
genes (1) 1
genes, ras (1) 1
growth factors (1) 1
hematology, oncology and palliative medicine (1) 1
humans (1) 1
index medicus (1) 1
leucovorin - administration & dosage (1) 1
male (1) 1
metastasis (1) 1
middle aged (1) 1
neoplasm metastasis (1) 1
oncology (1) 1
population (1) 1
predict (1) 1
product development (1) 1
response evaluation criteria in solid tumors (1) 1
shrinkage (1) 1
solid tumors (1) 1
studies (1) 1
survival (1) 1
tomography, x-ray computed (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
by Stintzing, Sebastian, Dr and Modest, Dominik P, MD and Rossius, Lisa and Lerch, Markus M, Prof and von Weikersthal, Ludwig Fischer, MD and Decker, Thomas, MD and Kiani, Alexander, MD and Vehling-Kaiser, Ursula, MD and Al-Batran, Salah-Eddin, Prof and Heintges, Tobias, MD and Lerchenmüller, Christian, MD and Kahl, Christoph, MD and Seipelt, Gernot, MD and Kullmann, Frank, MD and Stauch, Martina, MD and Scheithauer, Werner, Prof and Held, Swantje, MSc and Giessen-Jung, Clemens, MD and Moehler, Markus, Prof and Jagenburg, Andreas, MD and Kirchner, Thomas, Prof and Jung, Andreas, Prof and Heinemann, Volker, Prof and FIRE-3 Investigators and FIRE-3 investigators
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 10, pp. 1426 - 1434
Summary Background FIRE-3 compared first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in patients... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | 1ST-LINE TREATMENT | SOLID TUMORS | ONCOLOGY | SHRINKAGE | PREDICT | DEPTH | Colorectal Neoplasms - mortality | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - administration & dosage | Humans | Middle Aged | Male | Response Evaluation Criteria in Solid Tumors | Tomography, X-Ray Computed | Neoplasm Metastasis | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Cetuximab - administration & dosage | Female | Aged | Colorectal Neoplasms - pathology | Genes, ras | Camptothecin - analogs & derivatives | Antimitotic agents | Analysis | Genes | Colorectal cancer | Product development | Metastasis | Antineoplastic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.